Home ➤ Life Science ➤ Diagnostics ➤ Parkinson’s Disease Treatment Market
Parkinson’s Disease Treatment Market
Published date: Oct 2025 • Formats:
Request Sample Schedule a Call

Global Parkinson's Disease Treatment Market Analysis By Drug Class (Levodopa/Carbidopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Adenosine A2A Antagonists, Glutamate Antagonists, Cholinesterase Inhibitors, Others), By Disease Stage (Early-Stage, Advanced-Stage), By Route of Administration (Oral, Subcutaneous, Transdermal, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

  • Published date: Oct 2025
  • Report ID: 160750
  • Number of Pages: 391
  • Format:
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Market Snapshot
      • 1.3. Market Overview
      • 1.4. Segment Overview
      • 1.5. Regional Overview
      • 1.6. Competitive Landscape
      • 1.7. Taxonomy
      • 1.8. Industry Voices
    • 2. Global Market Overview
      • 2.1. Global Market Insights and Industry Overview
      • 2.2. Market Dynamics
        • 2.2.1. Drivers
        • 2.2.2. Restraints
        • 2.2.3. Opportunities
        • 2.2.4. Key Parkinson’s Disease Treatment Market Trends
      • 2.3. Disease Stage Landscape
      • 2.4. Regulatory Framework
      • 2.5. Sustainability and ESG (Environmental, Social, Governance)
      • 2.6. Opportunity Map Analysis
      • 2.7. Opportunity Orbits
      • 2.8. PESTLE Analysis
      • 2.9. PORTER’S Five Force Analysis
      • 2.10. Drivers & Restraints Impact Analysis
      • 2.11. Value Chain Analysis
        • 2.11.1. List of Raw Materials Suppliers
        • 2.11.2. List of Parkinson’s Disease Treatment Manufacturers
        • 2.11.3. List of Dealer/Distributors
      • 2.12. Regional Market Share and BPS Analysis
      • 2.13. Impact of Macro-economic Factors/Geopolitical Factors
    • 3. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Segment, 2020-2034
      • 3.1. Key Findings
      • 3.2. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
      • 3.3. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
        • 3.3.1. Levodopa/Carbidopa
          • 3.3.1.1. Insights
          • 3.3.1.2. Key Takeaways
        • 3.3.2. Dopamine Agonists
          • 3.3.2.1. Insights
          • 3.3.2.2. Key Takeaways
        • 3.3.3. MAO-B Inhibitors
          • 3.3.3.1. Insights
          • 3.3.3.2. Key Takeaways
        • 3.3.4. COMT Inhibitors
          • 3.3.4.1. Insights
          • 3.3.4.2. Key Takeaways
        • 3.3.5. Anticholinergics
          • 3.3.5.1. Insights
          • 3.3.5.2. Key Takeaways
        • 3.3.6. Adenosine A2A Antagonists
          • 3.3.6.1. Insights
          • 3.3.6.2. Key Takeaways
        • 3.3.7. Glutamate Antagonists
          • 3.3.7.1. Insights
          • 3.3.7.2. Key Takeaways
        • 3.3.8. Cholinesterase Inhibitors
          • 3.3.8.1. Insights
          • 3.3.8.2. Key Takeaways
        • 3.3.9. Others
          • 3.3.9.1. Insights
          • 3.3.9.2. Key Takeaways
      • 3.4. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
      • 3.5. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
        • 3.5.1. Early-Stage
          • 3.5.1.1. Insights
          • 3.5.1.2. Key Takeaways
        • 3.5.2. Advanced-Stage
          • 3.5.2.1. Insights
          • 3.5.2.2. Key Takeaways
      • 3.6. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
      • 3.7. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
        • 3.7.1. Oral
          • 3.7.1.1. Insights
          • 3.7.1.2. Key Takeaways
        • 3.7.2. Subcutaneous
          • 3.7.2.1. Insights
          • 3.7.2.2. Key Takeaways
        • 3.7.3. Transdermal
          • 3.7.3.1. Insights
          • 3.7.3.2. Key Takeaways
        • 3.7.4. Inhalation
          • 3.7.4.1. Insights
          • 3.7.4.2. Key Takeaways
      • 3.8. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 3.9. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
        • 3.9.1. Hospital Pharmacies
          • 3.9.1.1. Insights
          • 3.9.1.2. Key Takeaways
        • 3.9.2. Retail Pharmacies
          • 3.9.2.1. Insights
          • 3.9.2.2. Key Takeaways
        • 3.9.3. Online Pharmacies
          • 3.9.3.1. Insights
          • 3.9.3.2. Key Takeaways
    • 4. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Region, 2020-2034
      • 4.1. Key Findings
      • 4.2. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
        • 4.2.1. North America
          • 4.2.1.1. Regional Insights
        • 4.2.2. Europe
          • 4.2.2.1. Regional Insights
        • 4.2.3. Asia Pacific
          • 4.2.3.1. Regional Insights
        • 4.2.4. Latin America
          • 4.2.4.1. Regional Insights
        • 4.2.5. Middle East & Africa
          • 4.2.5.1. Regional Insights
      • 4.3. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Region
    • 5. North America Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
      • 5.1. Key Findings
      • 5.2. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
      • 5.3. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • 5.4. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
      • 5.5. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • 5.6. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
      • 5.7. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • 5.8. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 5.9. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • 5.10. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 5.11. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
        • 5.11.1. The US
        • 5.11.2. Canada
    • 6. Europe Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
      • 6.1. Key Findings
      • 6.2. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
      • 6.3. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • 6.4. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
      • 6.5. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • 6.6. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
      • 6.7. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • 6.8. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 6.9. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • 6.10. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 6.11. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
        • 6.11.1. Germany
        • 6.11.2. The UK
        • 6.11.3. France
        • 6.11.4. Spain
        • 6.11.5. Italy
        • 6.11.6. Russia
        • 6.11.7. Netherland
        • 6.11.8. Rest of Europe
    • 7. Asia Pacific Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
      • 7.1. Key Findings
      • 7.2. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
      • 7.3. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • 7.4. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
      • 7.5. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • 7.6. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
      • 7.7. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • 7.8. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 7.9. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • 7.10. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 7.11. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
        • 7.11.1. China
        • 7.11.2. Japan
        • 7.11.3. South Korea
        • 7.11.4. India
        • 7.11.5. Australia
        • 7.11.6. New Zealand
        • 7.11.7. Singapore
        • 7.11.8. Thailand
        • 7.11.9. Vietnam
        • 7.11.10. Rest of Asia Pacific
    • 8. Latin America Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
      • 8.1. Key Findings
      • 8.2. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
      • 8.3. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • 8.4. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
      • 8.5. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • 8.6. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
      • 8.7. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • 8.8. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 8.9. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • 8.10. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 8.11. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
        • 8.11.1. Brazil
        • 8.11.2. Mexico
        • 8.11.3. Rest of Latin America
    • 9. Middle East & Africa Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
      • 9.1. Key Findings
      • 9.2. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
      • 9.3. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • 9.4. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
      • 9.5. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • 9.6. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
      • 9.7. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • 9.8. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 9.9. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • 9.10. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 9.11. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
        • 9.11.1. South Africa
        • 9.11.2. Saudi Arabia
        • 9.11.3. UAE
        • 9.11.4. Rest of Middle East & Africa
    • 10. Competitive Landscape & Company Profiles
      • 10.1. Market Competition Scenario Analysis, By Company
        • 10.1.1. Key Takeaways
      • 10.2. Overview of Major Market Players
      • 10.3. Competitor Landscape
      • 10.4. Strategic Mapping
      • 10.5. Company Life Cycle Analysis
      • 10.6. Company Market Share Analysis
      • 10.7. Company Profiles
        • 10.7.1. AbbVie Inc.
          • 10.7.1.1. Company Details
          • 10.7.1.2. Business Overview
          • 10.7.1.3. Product Portfolio
          • 10.7.1.4. Financial Insights
          • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.1.6. SWOT Analysis
          • 10.7.1.7. Geographic Footprint
        • 10.7.2. Amgen Inc.
          • 10.7.2.1. Company Details
          • 10.7.2.2. Business Overview
          • 10.7.2.3. Product Portfolio
          • 10.7.2.4. Financial Insights
          • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.2.6. SWOT Analysis
          • 10.7.2.7. Geographic Footprint
        • 10.7.3. Teva Pharmaceutical Industries Ltd.
          • 10.7.3.1. Company Details
          • 10.7.3.2. Business Overview
          • 10.7.3.3. Product Portfolio
          • 10.7.3.4. Financial Insights
          • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.3.6. SWOT Analysis
          • 10.7.3.7. Geographic Footprint
        • 10.7.4. GlaxoSmithKline plc
          • 10.7.4.1. Company Details
          • 10.7.4.2. Business Overview
          • 10.7.4.3. Product Portfolio
          • 10.7.4.4. Financial Insights
          • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.4.6. SWOT Analysis
          • 10.7.4.7. Geographic Footprint
        • 10.7.5. Merck & Co., Inc.
          • 10.7.5.1. Company Details
          • 10.7.5.2. Business Overview
          • 10.7.5.3. Product Portfolio
          • 10.7.5.4. Financial Insights
          • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.5.6. SWOT Analysis
          • 10.7.5.7. Geographic Footprint
        • 10.7.6. Pfizer Inc.
          • 10.7.6.1. Company Details
          • 10.7.6.2. Business Overview
          • 10.7.6.3. Product Portfolio
          • 10.7.6.4. Financial Insights
          • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.6.6. SWOT Analysis
          • 10.7.6.7. Geographic Footprint
        • 10.7.7. UCB S.A.
          • 10.7.7.1. Company Details
          • 10.7.7.2. Business Overview
          • 10.7.7.3. Product Portfolio
          • 10.7.7.4. Financial Insights
          • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.7.6. SWOT Analysis
          • 10.7.7.7. Geographic Footprint
        • 10.7.8. Lundbeck A/S
          • 10.7.8.1. Company Details
          • 10.7.8.2. Business Overview
          • 10.7.8.3. Product Portfolio
          • 10.7.8.4. Financial Insights
          • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.8.6. SWOT Analysis
          • 10.7.8.7. Geographic Footprint
        • 10.7.9. Boehringer Ingelheim GmbH
          • 10.7.9.1. Company Details
          • 10.7.9.2. Business Overview
          • 10.7.9.3. Product Portfolio
          • 10.7.9.4. Financial Insights
          • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.9.6. SWOT Analysis
          • 10.7.9.7. Geographic Footprint
        • 10.7.10. Sanofi S.A.
          • 10.7.10.1. Company Details
          • 10.7.10.2. Business Overview
          • 10.7.10.3. Product Portfolio
          • 10.7.10.4. Financial Insights
          • 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.10.6. SWOT Analysis
          • 10.7.10.7. Geographic Footprint
        • 10.7.11. Sunovion Pharmaceuticals Inc.
          • 10.7.11.1. Company Details
          • 10.7.11.2. Business Overview
          • 10.7.11.3. Product Portfolio
          • 10.7.11.4. Financial Insights
          • 10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.11.6. SWOT Analysis
          • 10.7.11.7. Geographic Footprint
        • 10.7.12. Mylan N.V.
          • 10.7.12.1. Company Details
          • 10.7.12.2. Business Overview
          • 10.7.12.3. Product Portfolio
          • 10.7.12.4. Financial Insights
          • 10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.12.6. SWOT Analysis
          • 10.7.12.7. Geographic Footprint
        • 10.7.13. Roche Holding AG
          • 10.7.13.1. Company Details
          • 10.7.13.2. Business Overview
          • 10.7.13.3. Product Portfolio
          • 10.7.13.4. Financial Insights
          • 10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.13.6. SWOT Analysis
          • 10.7.13.7. Geographic Footprint
    • 11. Methodology and Data Source
      • 11.1. Methodology/Research Approach
      • 11.2. Market Size Estimation
      • 11.3. Market Breakdown and Data Triangulation
      • 11.4. Data Source
      • 11.5. Secondary Sources
      • 11.6. Primary Sources
      • 11.7. Appendix
      • 11.8. Disclaimer
    • List of Tables
      • Table 1. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 2. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 3. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 4. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 5. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Region, 2020-2034
      • Table 6. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 7. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 8. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 9. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 10. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
      • Table 11. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 12. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 13. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 14. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 15. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 16. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 17. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 18. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 19. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 20. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 21. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 22. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 23. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
      • Table 24. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 25. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 26. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 27. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 28. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 29. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 30. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 31. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 32. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 33. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 34. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 35. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 36. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 37. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 38. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 39. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 40. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 41. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 42. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 43. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 44. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 45. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 46. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 47. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 48. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 49. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 50. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 51. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 52. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 53. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 54. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 55. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 56. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 57. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 58. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 59. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 60. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
      • Table 61. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 62. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 63. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 64. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 65. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 66. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 67. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 68. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 69. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 70. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 71. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 72. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 73. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 74. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 75. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 76. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 77. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 78. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 79. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 80. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 81. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 82. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 83. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 84. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 85. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 86. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 87. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 88. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 89. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 90. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 91. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 92. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 93. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 94. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 95. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 96. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 97. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 98. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 99. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 100. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 101. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 102. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 103. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 104. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 105. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
      • Table 106. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 107. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 108. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 109. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 110. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 111. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 112. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 113. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 114. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 115. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 116. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 117. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 118. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 119. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 120. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 121. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 122. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
      • Table 123. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 124. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 125. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 126. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 127. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 128. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 129. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 130. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 131. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 132. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 133. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 134. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 135. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
      • Table 136. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
      • Table 137. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
      • Table 138. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
    • List of Figures
      • Figure 1. Global Parkinson’s Disease Treatment Market Snapshot: Market Value (US$ Mn), 2020-2034
      • Figure 2. Opportunity Map
      • Figure 3. Opportunity Orbit
      • Figure 4. Regional Market Share and BPS Analysis in Parkinson’s Disease Treatment Market
      • Figure 5. Global Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
      • Figure 6. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • Figure 7. Global Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
      • Figure 8. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • Figure 9. Global Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
      • Figure 10. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • Figure 11. Global Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 12. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • Figure 13. Global Parkinson’s Disease Treatment Market Analysis, By Region, 2020, 2024 and 2034
      • Figure 14. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Region
      • Figure 15. North America Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
      • Figure 16. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • Figure 17. North America Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
      • Figure 18. North America Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
      • Figure 19. North America Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
      • Figure 20. North America Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
      • Figure 21. North America Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
      • Figure 22. North America Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
      • Figure 23. North America Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
      • Figure 24. North America Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
      • Figure 25. North America Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
      • Figure 26. North America Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
      • Figure 27. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • Figure 28. North America Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
      • Figure 29. North America Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
      • Figure 30. North America Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
      • Figure 31. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • Figure 32. North America Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
      • Figure 33. North America Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
      • Figure 34. North America Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
      • Figure 35. North America Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
      • Figure 36. North America Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 37. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • Figure 38. North America Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 39. North America Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 40. North America Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 41. North America Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 42. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
      • Figure 43. Europe Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
      • Figure 44. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • Figure 45. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
      • Figure 46. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
      • Figure 47. Europe Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
      • Figure 48. Europe Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
      • Figure 49. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
      • Figure 50. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
      • Figure 51. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
      • Figure 52. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
      • Figure 53. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
      • Figure 54. Europe Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
      • Figure 55. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • Figure 56. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
      • Figure 57. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
      • Figure 58. Europe Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
      • Figure 59. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • Figure 60. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
      • Figure 61. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
      • Figure 62. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
      • Figure 63. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
      • Figure 64. Europe Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 65. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • Figure 66. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 67. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 68. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 69. Europe Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 70. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
      • Figure 71. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
      • Figure 72. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • Figure 73. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
      • Figure 74. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
      • Figure 75. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
      • Figure 76. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
      • Figure 77. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
      • Figure 78. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
      • Figure 79. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
      • Figure 80. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
      • Figure 81. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
      • Figure 82. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
      • Figure 83. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • Figure 84. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
      • Figure 85. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
      • Figure 86. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
      • Figure 87. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • Figure 88. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
      • Figure 89. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
      • Figure 90. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
      • Figure 91. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
      • Figure 92. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 93. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • Figure 94. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 95. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 96. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 97. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 98. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
      • Figure 99. Latin America Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
      • Figure 100. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • Figure 101. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
      • Figure 102. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
      • Figure 103. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
      • Figure 104. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
      • Figure 105. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
      • Figure 106. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
      • Figure 107. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
      • Figure 108. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
      • Figure 109. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
      • Figure 110. Latin America Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
      • Figure 111. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • Figure 112. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
      • Figure 113. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
      • Figure 114. Latin America Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
      • Figure 115. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • Figure 116. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
      • Figure 117. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
      • Figure 118. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
      • Figure 119. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
      • Figure 120. Latin America Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 121. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • Figure 122. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 123. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 124. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 125. Latin America Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 126. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
      • Figure 127. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
      • Figure 128. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
      • Figure 129. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
      • Figure 130. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
      • Figure 131. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
      • Figure 132. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
      • Figure 133. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
      • Figure 134. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
      • Figure 135. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
      • Figure 136. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
      • Figure 137. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
      • Figure 138. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
      • Figure 139. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
      • Figure 140. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
      • Figure 141. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
      • Figure 142. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Disease Stage 3, 2020-2034
      • Figure 143. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
      • Figure 144. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
      • Figure 145. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
      • Figure 146. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
      • Figure 147. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
      • Figure 148. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
      • Figure 149. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 150. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
      • Figure 151. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 152. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 153. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 154. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 155. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country

Related Reports

Our Clients

  • Our Clients
Parkinson’s Disease Treatment Market
  • 160750
  • Oct 2025
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options